Intersect ENT, Inc. (NASDAQ:XENT) CFO Jeryl L. Hilleman sold 12,833 shares of the firm’s stock in a transaction that occurred on Friday, August 4th. The stock was sold at an average price of $29.00, for a total transaction of $372,157.00. Following the transaction, the chief financial officer now directly owns 27,833 shares of the company’s stock, valued at $807,157. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Shares of Intersect ENT, Inc. (NASDAQ XENT) traded down 0.98% during trading on Friday, reaching $30.20. The company’s stock had a trading volume of 217,908 shares. Intersect ENT, Inc. has a 52-week low of $7.65 and a 52-week high of $31.90. The stock’s market cap is $881.51 million. The stock’s 50 day moving average price is $28.87 and its 200-day moving average price is $21.68.
Intersect ENT (NASDAQ:XENT) last issued its earnings results on Tuesday, August 1st. The medical equipment provider reported ($0.08) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.19) by $0.11. The business had revenue of $24 million for the quarter, compared to analysts’ expectations of $22.62 million. Intersect ENT had a negative return on equity of 17.60% and a negative net margin of 22.94%. The business’s revenue for the quarter was up 24.4% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.21) EPS. Equities analysts anticipate that Intersect ENT, Inc. will post ($0.61) EPS for the current year.
XENT has been the subject of several research reports. BidaskClub downgraded Intersect ENT from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 25th. Canaccord Genuity reaffirmed a “buy” rating on shares of Intersect ENT in a research note on Wednesday, May 3rd. Deutsche Bank AG set a $31.00 target price on Intersect ENT and gave the company a “buy” rating in a research report on Wednesday, August 2nd. TheStreet upgraded Intersect ENT from a “d” rating to a “c-” rating in a research report on Tuesday, August 1st. Finally, Northland Securities reiterated a “hold” rating and issued a $25.00 target price on shares of Intersect ENT in a research report on Wednesday, August 2nd. Five research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Intersect ENT has an average rating of “Buy” and an average price target of $23.13.
Several hedge funds have recently added to or reduced their stakes in XENT. Legal & General Group Plc raised its stake in Intersect ENT by 3.8% in the second quarter. Legal & General Group Plc now owns 6,939 shares of the medical equipment provider’s stock valued at $193,000 after buying an additional 255 shares during the last quarter. Moors & Cabot Inc. purchased a new stake in shares of Intersect ENT during the second quarter worth about $205,000. Cubist Systematic Strategies LLC purchased a new stake in shares of Intersect ENT during the second quarter worth about $229,000. Prudential Financial Inc. purchased a new stake in shares of Intersect ENT during the second quarter worth about $229,000. Finally, HighTower Advisors LLC purchased a new stake in shares of Intersect ENT during the second quarter worth about $231,000. 72.78% of the stock is currently owned by hedge funds and other institutional investors.
About Intersect ENT
Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.
Receive News & Ratings for Intersect ENT Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT Inc. and related companies with our FREE daily email newsletter.